Perineural Invasion and Survival in Pembrolizumab‐Treated Head and Neck Squamous Cell Carcinoma
The Laryngoscope · 2026-05 · 136 (5) · 2199-2205
DOI: 10.1002/lary.70350 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Laryngoscope, online erschienen am 03.01.2026. Verfasst von Angeline A Truong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine the relationship between perineural invasion and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on pembrolizumab.
Methods
This study was a retrospective, observational study performed at a tertiary care academic center. Participants included patients with oral cavity, oropharynx, hypopharynx, and laryngeal head and neck squamous cell carcinoma who began pembrolizumab treatment at UCSF between May 2016 and May 2022. The primary outcome was 6‐month progression‐free survival and 6‐month time‐to‐progression (TTP). The secondary outcome was 2‐year overall survival. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors.
Results
One hundred and thirty‐three patients with HNSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. Forty (30%) patients had perineural invasion. On univariate analysis, patients with perineural invasion were more likely to have worse 6‐month PFS ( p = 0.011). After controlling for number of metastatic organs, receipt of concurrent systemic therapy, age, and PDL‐1 status, presence of perineural invasion was associated with worse 6‐month PFS [HR 3.33 (1.32, 8.41), p = 0.011] and 6‐month time to progression (TTP) [HR 2.14 (1.09, 7.38), p = 0.032], but was not significantly associated with 2‐year OS [HR 1.35 (0.57, 3.19), p = 0.498].
Conclusion
Presence of perineural invasion is associated with poorer 6‐month progression‐free survival on ICI in patients with HNSCC. Future studies should further explore how perineural invasion may alter response to immunotherapy. Level of Evidence 3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
- Department of Microbiology and Immunology, University of California, San Francisco, California, USA.
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
- Department of Medicine, University of California, San Francisco, California, USA.
ORCID-Profile: Angeline A Truong, Rex H Lee, Ivan H El-Sayed, Mary Jue Xu, Patrick K Ha, Katherine C Wai
Zitieren
APA
Truong, A. A., Ho, S., Lee, R. H., Wu, X., Kang, H., El-Sayed, I. H., George, J. R., Heaton, C. M., Likhterov, I., Xu, M. J., Ha, P. K., Algazi, A. P., & Wai, K. C. (2026). Perineural Invasion and Survival in Pembrolizumab‐Treated Head and Neck Squamous Cell Carcinoma. The Laryngoscope, 136(5), 2199-2205. https://doi.org/10.1002/lary.70350
Vancouver
Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, et al. Perineural Invasion and Survival in Pembrolizumab‐Treated Head and Neck Squamous Cell Carcinoma. The Laryngoscope. 2026;136(5):2199-2205. doi:10.1002/lary.70350
BibTeX
@article{Truong2026,
author = {Truong, Angeline A and Ho, Savinnie and Lee, Rex H and Wu, Xin and Kang, Hyunseok and El-Sayed, Ivan H and George, Jonathan R and Heaton, Chase M and Likhterov, Ilya and Xu, Mary Jue and Ha, Patrick K and Algazi, Alain P and Wai, Katherine C},
title = {Perineural Invasion and Survival in Pembrolizumab‐Treated Head and Neck Squamous Cell Carcinoma},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {5},
pages = {2199--2205},
doi = {10.1002/lary.70350}
}
EUVIMED